{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cal K"],"funding":["U.S. Department of Health & Human Services | National Institutes of Health (NIH)","U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)","American Heart Association (American Heart Association, Inc.)"],"pagination":["1550-1569"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12373507"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(8)"],"pubmed_abstract":["The emergence of glucagon-like peptide-1 agonists represents a notable advancement in the pharmacological treatment of obesity, yet complementary approaches are essential. Through phenotypic drug discovery, we developed promising nitroalkene-containing small molecules for obesity-related metabolic dysfunctions. Here, we present SANA, a nitroalkene derivative of salicylate, demonstrating notable efficacy in preclinical models of diet-induced obesity. SANA reduces liver steatosis and insulin resistance by enhancing mitochondrial respiration and increasing creatine-dependent energy expenditure in adipose tissue, functioning effectively in thermoneutral conditions and independently of uncoupling protein 1 and AMPK activity. Finally, we conducted a randomized, double-blind, placebo-controlled p"],"journal":["Nature metabolism"],"pubmed_title":["A nitroalkene derivative of salicylate, SANA, induces creatine-dependent thermogenesis and promotes weight loss."],"pmcid":["PMC12373507"],"funding_grant_id":["R01 HL-128485","R01DK124510-01","R01HL153532","NS AI144004","R35GM119528","19TPA34850089","R01 HL-168290","NS 112727"],"pubmed_authors":["Cal K","DeVallance E","Ruiz S","Haag J","Agorrody G","Giri S","Benitez-Rosendo A","Lai de Souza LO","Peclat TR","Dapueto R","Verdes JM","Moyna G","Contreras P","Wang Y","Perez-Torrado V","Leyva A","Hollander JM","Breining P","Ingold M","Alves JM","de la Sovera V","Vilaseca C","White TA","Quijano C","Handy RM","Espasandin C","Galliussi G","Radi R","Rodriguez-Duarte J","Aicardo A","O'Doherty R","Leonardi R","Kamaid A","Du J","Mori MA","Garat MP","Bresque M","Lopez GV","Vendelbo MH","Colella L","Duran R","Escande C","Kelley EE","Chini EN","Santos L","Ziegler L","Calliari A","Valez V","Meadows E","Festuccia WT","Franca JV","Holloway GP","Leiria LO","Lopez A","Santana Barbosa GC","King R","Thompson KL","Lino CA","Porcal W","Camacho-Pereira J","Chichierchio MS","Rattan R","Lewis SE","Jakobsen S","Vieira TS","Menezes Dos Reis L","Batthyany C","Moraes-Vieira P"],"additional_accession":[]},"is_claimable":false,"name":"A nitroalkene derivative of salicylate, SANA, induces creatine-dependent thermogenesis and promotes weight loss.","description":"The emergence of glucagon-like peptide-1 agonists represents a notable advancement in the pharmacological treatment of obesity, yet complementary approaches are essential. Through phenotypic drug discovery, we developed promising nitroalkene-containing small molecules for obesity-related metabolic dysfunctions. Here, we present SANA, a nitroalkene derivative of salicylate, demonstrating notable efficacy in preclinical models of diet-induced obesity. SANA reduces liver steatosis and insulin resistance by enhancing mitochondrial respiration and increasing creatine-dependent energy expenditure in adipose tissue, functioning effectively in thermoneutral conditions and independently of uncoupling protein 1 and AMPK activity. Finally, we conducted a randomized, double-blind, placebo-controlled p","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-05-09T10:43:46.075Z","creation":"2026-04-08T00:47:57.123Z"},"accession":"S-EPMC12373507","cross_references":{"pubmed":["40527924"],"doi":["10.1038/s42255-025-01311-z"]}}